

Publikationen seit 2010

1. Zhang, W., Y. Yu, F. Hertwig, J. Thierry-Mieg, W. Zhang, D. Thierry-Mieg, J. Wang, C. Furlanello, V. Devanarayan, J. Cheng, Y. Deng, B. Hero, H. Hong, M. Jia, L. Li, S.M. Lin, Y. Nikolsky, A. Oberthuer, T. Qing, Z. Su, R. Volland, C. Wang, M.D. Wang, J. Ai, D. Albanese, S. Asgharzadeh, S. Avigad, W. Bao, M. Bessarabova, M.H. Brilliant, B. Brors, M. Chierici, T.M. Chu, J. Zhang, R.G. Grundy, M.M. He, S. Hebring, H.L. Kaufman, S. Lababidi, L.J. Lancashire, Y. Li, X.X. Lu, H. Luo, X. Ma, B. Ning, R. Noguera, M. Peifer, J.H. Phan, F. Roels, C. Rosswog, S. Shao, J. Shen, J. Theissen, G.P. Tonini, J. Vandesompele, P.Y. Wu, W. Xiao, J. Xu, W. Xu, J. Xuan, Y. Yang, Z. Ye, Z. Dong, K.K. Zhang, Y. Yin, C. Zhao, Y. Zheng, R.D. Wolfinger, T. Shi, L.H. Malkas, F. Berthold, J. Wang, W. Tong, L. Shi, Z. Peng, and M. Fischer, Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. *Genome Biol*, 2015. 16: p. 133.
2. van Wezel, E.M., J. Stutterheim, F. Vree, L. Zappeij-Kannegieter, B. Decarolis, B. Hero, F. Berthold, R. Schumacher-Kuckelkorn, T. Simon, M. Fiocco, C. Voermans, M.M. van Noesel, H.N. Caron, C.E. van der Schoot, G.A. Tytgat, and G.M.S. Group, Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. *Pediatr Blood Cancer*, 2015. 62(8): p. 1368-73.
3. Spix, C., F. Berthold, B. Hero, J. Michaelis, and F.H. Schilling, Correction factors for self-selection when evaluating screening programmes. *J Med Screen*, 2015.
4. Schramm, A., J. Koster, Y. Assenov, K. Althoff, M. Peifer, E. Mahlow, A. Odersky, D. Beisser, C. Ernst, A.G. Henssen, H. Stephan, C. Schroder, L. Heukamp, A. Engesser, Y. Kahlert, J. Theissen, B. Hero, F. Roels, J. Altmüller, P. Nürnberg, K. Astrahantseff, C. Gloeckner, K. De Preter, C. Plass, S. Lee, H.N. Lode, K.O. Henrich, M. Gartlgruber, F. Speleman, P. Schmezer, F. Westermann, S. Rahmann, M. Fischer, A. Eggert, and J.H. Schulte, Mutational dynamics between primary and relapse neuroblastomas. *Nat Genet*, 2015. 47(8): p. 872-7.
5. Schmidt, R., R. Kwiecien, A. Faldum, F. Berthold, B. Hero, and S. Ligges, Sample size calculation for the one-sample log-rank test. *Stat Med*, 2015. 34(6): p. 1031-40.
6. Peinemann, F., E.C. van Dalen, D.A. Tushabe, and F. Berthold, Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation. *Cochrane Database Syst Rev*, 2015. 1: p. CD010685.
7. Peinemann, F., D.A. Tushabe, E.C. van Dalen, and F. Berthold, Rapid COJEC versus standard induction therapies for high-risk neuroblastoma. *Cochrane Database Syst Rev*, 2015. 5: p. CD010774.
8. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Krämer A, Roncaioli JL, Sand F, Heuckmann J, Ikram F, Schmidt R, Ackermann S, Engesser A, Kahlert Y, Vogel W, Altmüller J, Nürnberg P, Thierry-Mieg J, Thierry-Mieg D, Mariappan A, Heynck S, Mariotti E, Henrich KO, Glöckner C, Bosco G, Leuschner I, Schweiger MR, Savelyeva L, Watkins SC, Shao C, Bell E, Höfer T, Achter V, Lang U, Theissen J, Volland R, Saadati M, Eggert A, de Wilde B, Berthold F, Peng Z, Zhao C, Shi L, Ortmann M, Büttner R, Perner S, Hero B, Schramm A, Schulte JH, Herrmann C, O'Sullivan RJ, Westermann F, Thomas RK, Fischer M. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. *Nature*, in press.

9. Oberthuer, A., D. Juraeva, B. Hero, R. Volland, C. Sterz, R. Schmidt, A. Faldum, Y. Kahlert, A. Engesser, S. Asgharzadeh, R. Seeger, M. Ohira, A. Nakagawara, P. Scaruffi, G.P. Tonini, I. Janoueix-Lerosey, O. Delattre, G. Schleiermacher, J. Vandesompele, F. Speleman, R. Noguera, M. Piqueras, J. Benard, A. Valent, S. Avigad, I. Yaniv, R.G. Grundy, M. Ortmann, C. Shao, M. Schwab, R. Eils, T. Simon, J. Theissen, F. Berthold, F. Westermann, B. Brors, and M. Fischer, Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. *Clin Cancer Res*, 2015. 21(8): p. 1904-15.
10. Mauz-Korholz, C., D. Hasenclever, V. Holzendorf, M. Bernstadt, H. Jurgens, S. Burdach, A. Eggert, F. Berthold, H.L. Muller, M.C. Fruhwald, T. Klingebiel, M. Metzler, and D. Korholz, Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial. *Leuk Lymphoma*, 2015. 56(5): p. 1308-14.
11. Lindner, S., H.S. Bachmann, A. Odersky, S. Schaefer, L. Klein-Hitpass, B. Hero, M. Fischer, A. Eggert, A. Schramm, and J.H. Schulte, Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. *Biomed Rep*, 2015. 3(4): p. 443-446.
12. Lau, D.T., C.L. Flemming, S. Gherardi, G. Perini, A. Oberthuer, M. Fischer, D. Juraeva, B. Brors, C. Xue, M.D. Norris, G.M. Marshall, M. Haber, J.I. Fletcher, and L.J. Ashton, MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma. *Oncotarget*, 2015. 6(17): p. 15510-23.
13. Kuhn, J.P., F. Berthold, J. Mayerle, H. Volzke, S.B. Reeder, W. Rathmann, M.M. Lerch, N. Hosten, K. Hegenscheid, and P.J. Meffert, Pancreatic Steatosis Demonstrated at MR Imaging in the General Population: Clinical Relevance. *Radiology*, 2015. 276(1): p. 129-36.
14. Bleeker, G., B.L. van Eck-Smit, K.H. Zwinderman, R. Versteeg, M.M. van Noesel, B.L. Kam, G.J. Kaspers, A. van Schie, S.G. Kreissman, G. Yanik, B. Hero, M. Schmidt, G. Laureys, B. Lambert, I. Ora, J.H. Schulte, H.N. Caron, and G.A. Tytgat, MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. *Eur J Nucl Med Mol Imaging*, 2015. 42(2): p. 222-30.
15. Walz, S., F. Lorenzin, J. Morton, K.E. Wiese, B. von Eyss, S. Herold, L. Rycak, H. Dumay-Odelot, S. Karim, M. Bartkuhn, F. Roels, T. Wustefeld, M. Fischer, M. Teichmann, L. Zender, C.L. Wei, O. Sansom, E. Wolf, and M. Eilers, Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. *Nature*, 2014. 511(7510): p. 483-7.
16. Vo, K.T., K.K. Matthay, J. Neuhaus, W.B. London, B. Hero, P.F. Ambros, A. Nakagawara, D. Miniati, K. Wheeler, A.D. Pearson, S.L. Cohn, and S.G. DuBois, Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. *J Clin Oncol*, 2014. 32(28): p. 3169-76.
17. Theissen, J., A. Oberthuer, A. Hombach, R. Volland, F. Hertwig, M. Fischer, R. Spitz, M. Zapatka, B. Brors, M. Ortmann, T. Simon, B. Hero, and F. Berthold, Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma. *Genes Chromosomes Cancer*, 2014. 53(8): p. 639-49.
18. Su, Z., H. Fang, H. Hong, L. Shi, W. Zhang, W. Zhang, Y. Zhang, Z. Dong, L.J.

Lancashire, M. Bessarabova, X. Yang, B. Ning, B. Gong, J. Meehan, J. Xu, W. Ge, R. Perkins, M. Fischer, and W. Tong, An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era. *Genome Biol*, 2014. 15(12): p. 523.

19. Su Z, Łabaj PP, Li S, Thierry-Mieg J, Thierry-Mieg D, Shi W, Wang C, Schroth GP, Setterquist RA, Thompson JF, Jones WD, Xiao W, Xu W, Jensen RV, Kelly R, Xu J, Conesa A, Furlanello C, Gao H, Hong H, Jafari N, Letovsky S, Liao Y, Lu F, Oakeley EJ, Peng Z, Praul CA, Santoyo-Lopez J, Scherer A, Shi T, Smyth GK, Staedtler F, Sykacek P, Tan XX, Thompson EA, Vandesompele J, Wang MD, Wang J, Wolfinger RD, Zavadil J, Auerbach SS, Bao W, Binder H, Blomquist T, Brilliant MH, Bushel PR, Cai W, Catalano JG, Chang CW, Chen T, Chen G, Chen R, Chierici M, Chu TM, Clevert DA, Deng Y, Derti A, Devanarayan V, Dong Z, Dopazo J, Du T, Fang H, Fang Y, Fasold M, Fernandez A, Fischer M, Furió-Tari P, Fuscoe JC, Gaj S, Gandara J, Gao H, Ge W, Gondo Y, Gong B, Gong M, Gong Z, Green B, Guo C, Guo L, Guo LW, Hadfield J, Hellemans J, Hochreiter S, Jia M, Jian M, Johnson CD, Kay S, Kleinjans J, Lababidi S, Levy S, Li QZ, Li L, Li L, Li P, Li Y, Li H, Li J, Li S, Lin SM, López FJ, Lu X, Luo H, Ma X, Meehan J, Megherbi DB, Mei N, Mu B, Ning B, Pandey A, Pérez-Florido J, Perkins RG, Peters R, Phan JH, Pirooznia M, Qian F, Qing T, Rainbow L, Rocca-Serra P, Sambourg L, Sansone SA, Schwartz S, Shah R, Shen J, Smith TM, Stegle O, Stralis-Pavese N, Stupka E, Suzuki Y, Szkotnicki LT, Tinning M, Tu B, van Delft J, Vela A, Venturini E, Walker SJ, Wan L, Wang W, Wang J, Wang J, Wieben ED, Willey JC, Wu PY, Xuan J, Yang Y, Ye Z, Yin Y, Yu Y, Yuan YC, Zhang J, Zhang KK, Zhang W, Zhang W, Zhang Y, Zhao C, Zheng Y, Zhou Y, Zumbo P, Tong W, Kreil DP, Mason CE, Shi L. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequence Quality Control consortium. *Nat Biotechnol*, 2014, 32(9): 903-914.
20. Simon T. Handlungsempfehlungen nach der Leitlinie "Neuroblastom". *Monatschr Kinderheilkunde*, 2014; 162: 257-258
21. Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, Fransson S, Ganeshram A, Mondal T, Bandaru S, Östensson M, Akyürek LM, Abrahamsson J, Pfeifer S, Larsson E, Shi L, Peng Z, Fischer M, Martinsson T, Hedborg F, Kogner P, Kanduri C. Neuroblastoma transcriptome sequencing reveals a risk associated long noncoding RNA NBAT-1 that controls tumor progression via regulating cell proliferation and neuronal differentiation. *Cancer Cell*, 2014, 26(5): 722-737.
22. Mosse, Y.P., R.J. Deyell, F. Berthold, A. Nagakawara, P.F. Ambros, T. Monclair, S.L. Cohn, A.D. Pearson, W.B. London, and K.K. Matthay, Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. *Pediatr Blood Cancer*, 2014. 61(4): p. 627-35.
23. Morgenstern, D.A., W.B. London, D. Stephens, S.L. Volchenboum, B. Hero, A. Di Cataldo, A. Nakagawara, H. Shimada, P.F. Ambros, K.K. Matthay, S.L. Cohn, A.D. Pearson, and M.S. Irwin, Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. *J Clin Oncol*, 2014. 32(12): p. 1228-35.

24. Meany, H.J., W.B. London, P.F. Ambros, K.K. Matthay, T. Monclair, T. Simon, A. Garaventa, F. Berthold, A. Nakagawara, S.L. Cohn, A.D. Pearson, and J.R. Park, Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. *Pediatr Blood Cancer*, 2014. 61(11): p. 1932-9.
25. Fabian, J., M. Lodrini, I. Oehme, M.C. Schier, T.M. Thole, T. Hielscher, A. Kopp-Schneider, L. Opitz, D. Capper, A. von Deimling, I. Wiegand, T. Milde, U. Mahlke, F. Westermann, O. Popanda, F. Roels, B. Hero, F. Berthold, M. Fischer, A.E. Kulozik, O. Witt, and H.E. Deubzer, GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. *Cancer Res*, 2014. 74(9): p. 2604-16.
26. Dreidax, D., S. Bannert, K.O. Henrich, C. Schroder, S. Bender, C.C. Oakes, S. Lindner, J.H. Schulte, D. Duffy, T. Schwarzl, M. Saadati, V. Ehemann, A. Benner, S. Pfister, M. Fischer, and F. Westermann, p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. *Hum Mol Genet*, 2014. 23(25): p. 6826-37.
27. Brecht, I.B., C. Bremensdorfer, D.T. Schneider, M.C. Fruhwald, S. Offenmuller, R. Mertens, P. Vorwerk, E. Koscielniak, S.S. Bielack, M. Benesch, B. Hero, N. Graf, D. von Schweinitz, and P. Kaatsch, Rare malignant pediatric tumors registered in the German Childhood Cancer Registry 2001-2010. *Pediatr Blood Cancer*, 2014. 61(7): p. 1202-9.
28. Bouche, G., N. Andre, S. Banavali, F. Berthold, A. Berruti, G. Bocci, G. Brandi, U. Cavallaro, S. Cinieri, M. Colleoni, G. Curigliano, T. Di Desidero, A. Eniu, N. Fazio, R. Kerbel, L. Hutchinson, U. Ledzewicz, E. Munzone, E. Pasquier, O. Graciela Scharovsky, Y. Shaked, J. Sterba, M. Villalba, and F. Bertolini, Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. *Ecancermedicalscience*, 2014. 8: p. 463.
29. Ackermann, S., H. Kocak, B. Hero, V. Ehemann, Y. Kahlert, A. Oberthuer, F. Roels, J. Theissen, M. Odenthal, F. Berthold, and M. Fischer, FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma. *BMC Cancer*, 2014. 14: p. 840.
30. Tolosi, L., J. Theissen, K. Halachev, B. Hero, F. Berthold, and T. Lengauer, A method for finding consensus breakpoints in the cancer genome from copy number data. *Bioinformatics*, 2013. 29(14): p. 1793-800.
31. Simon, T., B. Haberle, B. Hero, D. von Schweinitz, and F. Berthold, Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. *J Clin Oncol*, 2013. 31(6): p. 752-8.
32. Schulte, J.H., S. Schulte, L.C. Heukamp, K. Astrahantseff, H. Stephan, M. Fischer, A. Schramm, and A. Eggert, Targeted Therapy for Neuroblastoma: ALK Inhibitors. *Klin Padiatr*, 2013. 225(6): p. 303-8.
33. Schelhorn, S.E., M. Fischer, L. Tolosi, J. Altmuller, P. Nurnberg, H. Pfister, T. Lengauer, and F. Berthold, Sensitive detection of viral transcripts in human tumor transcriptomes. *PLoS Comput Biol*, 2013. 9(10): p. e1003228.
34. Rossig, C., H. Juergens, M. Schrappe, A. Moericke, G. Henze, A. von Stackelberg, D. Reinhardt, B. Burkhardt, W. Woessmann, M. Zimmermann, H. Gadner, G. Mann, G. Schellong, C. Mauz-Koerholz, U. Dirksen, S. Bielack, F. Berthold, N. Graf, S. Rutkowski, G. Calaminus, P. Kaatsch, and U. Creutzig, Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. *Pediatr Blood Cancer*, 2013.

60(10): p. 1574-81.

35. Lodrini M, Oehme I, Schroeder C, Milde T, Schier M, Kopp-Schneider A, Schulte J, Fischer M, De Preter K, Pattyn F, Castoldi M, Muckenthaler M, Kulozik A, Westermann F, Witt O, Deubzer H. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. *Nucleic Acids Res*, 2013, 41(12): 6018-6033.
36. Kocak, H., S. Ackermann, B. Hero, Y. Kahlert, A. Oberthuer, D. Juraeva, F. Roels, J. Theissen, F. Westermann, H. Deubzer, V. Ehemann, B. Brors, M. Odenthal, F. Berthold, and M. Fischer, Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma. *Cell Death Dis*, 2013. 4: p. e586.
37. Kickingeder, P., P. Willeit, T. Simon, and M.I. Ruge, Diagnostic value and safety of stereotactic biopsy for brainstem tumors: a systematic review and meta-analysis of 1480 cases. *Neurosurgery*, 2013. 72(6): p. 873-81; discussion 882; quiz 882.
38. Hero, B. and G. Schleiermacher, Update on pediatric opsoclonus myoclonus syndrome. *Neuropediatrics*, 2013. 44(6): p. 324-9.
39. Dreidax, D., S. Gogolin, C. Schroeder, D. Muth, L.M. Brueckner, E.M. Hess, M. Zapatka, J. Theissen, M. Fischer, V. Ehemann, M. Schwab, L. Savelyeva, and F. Westermann, Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis. *Hum Mol Genet*, 2013. 22(9): p. 1735-45.
40. Decarolis, B., C. Schneider, B. Hero, T. Simon, R. Volland, F. Roels, M. Dietlein, F. Berthold, and M. Schmidt, Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. *J Clin Oncol*, 2013. 31(7): p. 944-51.
41. Brockmann, M., E. Poon, T. Berry, A. Carstensen, H.E. Deubzer, L. Rycak, Y. Jamin, K. Thway, S.P. Robinson, F. Roels, O. Witt, M. Fischer, L. Chesler, and M. Eilers, Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. *Cancer Cell*, 2013. 24(1): p. 75-89.
42. Aschoff, M., A. Hotz-Wagenblatt, K.H. Glatting, M. Fischer, R. Eils, and R. Konig, SplicingCompass: differential splicing detection using RNA-seq data. *Bioinformatics*, 2013. 29(9): p. 1141-8.
43. Tonini, G.P., A. Nakagawara, and F. Berthold, Towards a turning point of neuroblastoma therapy. *Cancer Lett*, 2012. 326(2): p. 128-34.
44. Stigliani, S., S. Coco, S. Moretti, A. Oberthuer, M. Fischer, J. Theissen, F. Gallo, A. Garavento, F. Berthold, S. Bonassi, G.P. Tonini, and P. Scaruffi, High genomic instability predicts survival in metastatic high-risk neuroblastoma. *Neoplasia*, 2012. 14(9): p. 823-32.
45. Simon, T., C.A. Niemann, B. Hero, G. Henze, M. Suttrop, F.H. Schilling, and F. Berthold, Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. *Dev Med Child Neurol*, 2012. 54(4): p. 347-52.
46. Schneider, C., T. Simon, B. Hero, U.S. Uphoff, U. Drebber, H. Alakus, E. Holinski-Feder, F. Berthold, M. Dietlein, and M.C. Schmidt, [18F]Fluorodeoxyglucose positron emission tomography/computed tomography-positive gastric adenocarcinoma in a 12-year-old girl with Peutz-Jeghers syndrome. *J Clin Oncol*, 2012. 30(14): p. e140-3.
47. Schleiermacher, G., V. Mosseri, W.B. London, J.M. Maris, G.M. Brodeur, E. Attiyeh, M.

- Haber, J. Khan, A. Nakagawara, F. Speleman, R. Noguera, G.P. Tonini, M. Fischer, I. Ambros, T. Monclair, K.K. Matthay, P. Ambros, S.L. Cohn, and A.D. Pearson, Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. *Br J Cancer*, 2012. 107(8): p. 1418-22.
48. Ruge, M.I., P. Kickingeder, T. Simon, H. Treuer, and V. Sturm, Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome. *J Neurooncol*, 2012. 109(2): p. 273-83.
 49. Oberthuer, A., Berthold, F., Hero, B., Till, H., Neuroblastome, in *Solide Tumoren im Kindesalter*, J. Fuchs, Editor. 2012, Schattauer GmbH: Stuttgart. p. 77-110.
 50. Molenaar, J.J., R. Domingo-Fernandez, M.E. Ebus, S. Lindner, J. Koster, K. Drabek, P. Mestdagh, P. van Sluis, L.J. Valentijn, J. van Nes, M. Broekmans, F. Haneveld, R. Volckmann, I. Bray, L. Heukamp, A. Sprussel, T. Thor, K. Kieckbusch, L. Klein-Hitpass, M. Fischer, J. Vandesompele, A. Schramm, M.M. van Noesel, L. Varesio, F. Speleman, A. Eggert, R.L. Stallings, H.N. Caron, R. Versteeg, and J.H. Schulte, LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. *Nat Genet*, 2012. 44(11): p. 1199-206.
 51. Michaelis, M., N. Hinsch, U.R. Michaelis, F. Rothweiler, T. Simon, H.W. ilhelm Doerr, J. Cinatl, and J. Cinatl, Jr., Chemotherapy-associated angiogenesis in neuroblastoma tumors. *Am J Pathol*, 2012. 180(4): p. 1370-7.
 52. Hopker, K., H. Hagmann, S. Khurshid, S. Chen, P. Hasskamp, T. Seeger-Nukpezah, K. Schilberg, L. Heukamp, T. Lamkemeyer, M.L. Sos, R.K. Thomas, D. Lowery, F. Roels, M. Fischer, M.C. Liebau, U. Resch, T. Kisner, F. Rother, M.P. Bartram, R.U. Muller, F. Fabretti, P. Kurschat, B. Schumacher, M. Gaestel, R.H. Medema, M.B. Yaffe, B. Schermer, H.C. Reinhardt, and T. Benzing, AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. *EMBO J*, 2012. 31(20): p. 3961-75.
 53. Garcia, I., G. Mayol, J. Rios, G. Domenech, N.K. Cheung, A. Oberthuer, M. Fischer, J.M. Maris, G.M. Brodeur, B. Hero, E. Rodriguez, M. Sunol, P. Galvan, C. de Torres, J. Mora, and C. Lavarino, A three-gene expression signature model for risk stratification of patients with neuroblastoma. *Clin Cancer Res*, 2012. 18(7): p. 2012-23.
 54. Frommolt, P., A.T. Abdallah, J. Altmuller, S. Motameny, H. Thiele, C. Becker, K. Stemshorn, M. Fischer, T. Freiling, and P. Nurnberg, Assessing the enrichment performance in targeted resequencing experiments. *Hum Mutat*, 2012. 33(4): p. 635-41.
 55. Coco, S., J. Theissen, P. Scaruffi, S. Stigliani, S. Moretti, A. Oberthuer, F. Valdora, M. Fischer, F. Gallo, B. Hero, S. Bonassi, F. Berthold, and G.P. Tonini, Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. *Int J Cancer*, 2012. 131(7): p. 1591-600.
 56. Asgharzadeh, S., J.A. Salo, L. Ji, A. Oberthuer, M. Fischer, F. Berthold, M. Hadjidaniel, C.W. Liu, L.S. Metelitsa, R. Pique-Regi, P. Wakamatsu, J.G. Villablanca, S.G. Kreissman, K.K. Matthay, H. Shimada, W.B. London, R. Sposto, and R.C. Seeger, Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. *J Clin Oncol*, 2012. 30(28): p. 3525-32.
 57. Simon, T., B. Hero, A. Faldum, R. Handgretinger, M. Schrappe, T. Klingebiel, and F. Berthold, Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. *BMC Cancer*, 2011. 11: p. 21.
 58. Simon, T., F. Berthold, A. Borkhardt, B. Kremens, B. De Carolis, and B. Hero, Treatment

and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. *Pediatr Blood Cancer*, 2011. 56(4): p. 578-83.

59. Schulte, J.H., H.S. Bachmann, B. Brockmeyer, K. Depreter, A. Oberthur, S. Ackermann, Y. Kahlert, K. Pajtler, J. Theissen, F. Westermann, J. Vandesompele, F. Speleman, F. Berthold, A. Eggert, B. Brors, B. Hero, A. Schramm, and M. Fischer, High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. *Clin Cancer Res*, 2011. 17(15): p. 5082-92.
60. Schmitt, J., A. Keller, N. Nourkani-Tutdibi, S. Heisel, N. Habel, P. Leidinger, N. Ludwig, M. Gessler, N. Graf, F. Berthold, H.P. Lenhof, and E. Meese, Autoantibody signature differentiates Wilms tumor patients from neuroblastoma patients. *PLoS One*, 2011. 6(12): p. e28951.
61. Ruge, M.I., T. Simon, B. Suchorska, R. Lehrke, C. Hamisch, F. Koerber, M. Maarouf, H. Treuer, F. Berthold, V. Sturm, and J. Voges, Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome. *J Clin Oncol*, 2011. 29(31): p. 4151-9.
62. Paulides, M., W. Stohr, H.J. Laws, N. Graf, M. Lakomek, F. Berthold, K. Schmitt, F. Niggli, H. Jurgens, S. Bielack, E. Koscielniak, T. Klingebiel, and T. Langer, Antibody levels against tetanus and diphtheria after polychemotherapy for childhood sarcoma: a report from the Late Effects Surveillance System. *Vaccine*, 2011. 29(8): p. 1565-8.
63. Pasquier, E., M.W. Kieran, J. Sterba, Y. Shaked, S. Baruchel, O. Oberlin, M.S. Kivivuori, A. Peyrl, M. Diawarra, M. Casanova, S. Zacharoulis, G. Vassal, F. Berthold, A. Verschuur, and N. Andre, Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. *Transl Oncol*, 2011. 4(4): p. 203-11.
64. Muller, K., I. Zwiener, H. Welker, E. Maass, R. Bongartz, F. Berthold, T. Pietsch, M. Warmuth-Metz, A. von Bueren, and S. Rutkowski, Curative treatment for central nervous system medulloepithelioma despite residual disease after resection. Report of two cases treated according to the GPHO Protocol HIT 2000 and review of the literature. *Strahlenther Onkol*, 2011. 187(11): p. 757-62.
65. Moroz, V., D. Machin, A. Faldum, B. Hero, T. Iehara, V. Mosseri, R. Ladenstein, B. De Bernardi, H. Rubie, F. Berthold, K.K. Matthay, T. Monclair, P.F. Ambros, A.D. Pearson, S.L. Cohn, and W.B. London, Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. *Eur J Cancer*, 2011. 47(4): p. 561-71.
66. London, W.B., V. Castel, T. Monclair, P.F. Ambros, A.D. Pearson, S.L. Cohn, F. Berthold, A. Nakagawara, R.L. Ladenstein, T. Iehara, and K.K. Matthay, Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. *J Clin Oncol*, 2011. 29(24): p. 3286-92.
67. Kramm, C.M., S. Butenhoff, U. Rausche, M. Warmuth-Metz, R.D. Kortmann, T. Pietsch, A. Gnekow, N. Jorch, G. Janssen, F. Berthold, and J.E. Wolff, Thalamic high-grade gliomas in children: a distinct clinical subset? *Neuro Oncol*, 2011. 13(6): p. 680-9.
68. Hero, B., Berthold, F., Neuroblastoma. 2011.
69. Henrich, K.O., T. Bauer, J. Schulte, V. Ehemann, H. Deubzer, S. Gogolin, D. Muth, M. Fischer, A. Benner, R. Konig, M. Schwab, and F. Westermann, CAMTA1, a 1p36 tumor

suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells. *Cancer Res*, 2011. 71(8): p. 3142-51.

70. Feichtinger, R.G., D. Neureiter, J.A. Mayr, F.A. Zimmermann, F. Berthold, N. Jones, W. Sperl, and B. Kofler, Loss of mitochondria in ganglioneuromas. *Front Biosci (Elite Ed)*, 2011. 3: p. 179-86.
71. El Majdoub, F., T. Simon, M. Hoevels, F. Berthold, V. Sturm, and M. Maarouf, Interstitial brachytherapy using stereotactic implanted (125)iodine seeds for recurrent medulloblastoma. *Clin Oncol (R Coll Radiol)*, 2011. 23(8): p. 532-7.
72. Coco, S., F. Valdora, S. Bonassi, P. Scaruffi, S. Stigliani, A. Oberthuer, F. Berthold, I. Andolfo, T. Servidei, R. Riccardi, E. Basso, A. Iolascon, and G.P. Tonini, Chromosome 9q and 16q loss identified by genome-wide pooled-analysis are associated with tumor aggressiveness in patients with classic medulloblastoma. *OMICS*, 2011. 15(5): p. 273-80.
73. Brisse, H.J., M.B. McCarville, C. Granata, K.B. Krug, S.L. Wootton-Gorges, K. Kanegawa, F. Giammarile, M. Schmidt, B.L. Shulkin, K.K. Matthay, V.J. Lewington, S. Sarnacki, B. Hero, M. Kaneko, W.B. London, A.D. Pearson, S.L. Cohn, T. Monclair, and P. International Neuroblastoma Risk Group, Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. *Radiology*, 2011. 261(1): p. 243-57.
74. Afanasyeva, E.A., P. Mestdagh, C. Kumps, J. Vandesompele, V. Ehemann, J. Theissen, M. Fischer, M. Zapatka, B. Brors, L. Savelyeva, V. Sagulenko, F. Speleman, M. Schwab, and F. Westermann, MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. *Cell Death Differ*, 2011. 18(6): p. 974-84.
75. Ackermann, S., F. Goeser, J.H. Schulte, A. Schramm, V. Ehemann, B. Hero, A. Eggert, F. Berthold, and M. Fischer, Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. *Clin Cancer Res*, 2011. 17(4): p. 731-41.
76. Wachowiak, R., H. Till, R. Metzger, U. Bierbach, T. Simon, B. Sattler, T. Aigner, O. Sabri, and R. Kluge, Residual lymph node metastasis in stage 4 neuroblastoma--advantage of radio-guided surgery? *Pediatr Hematol Oncol*, 2010. 27(6): p. 471-5.
77. Sudbrock, F., M. Schmidt, T. Simon, W. Eschner, F. Berthold, and H. Schicha, Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, pheochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging*, 2010. 37(7): p. 1279-90.
78. Simon, T., J. Kohlhase, C. Wilhelm, M. Kochanek, B. De Carolis, and F. Berthold, Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review. *Am J Med Genet A*, 2010. 152A(6): p. 1575-9.
79. Simon, T., M. Feldkotter, K. Buiting, M. Ortmann, H. Bolz, and F. Korber, Slow progression of a small Wilms' tumor. *Klin Padiatr*, 2010. 222(3): p. 190-1.
80. Shi, L., G. Campbell, W.D. Jones, F. Campagne, Z. Wen, S.J. Walker, Z. Su, T.M. Chu, F.M. Goodsaid, L. Pusztai, J.D. Shaughnessy, Jr., A. Oberthuer, R.S. Thomas, R.S. Paules, M. Fielden, B. Barlogie, W. Chen, P. Du, M. Fischer, C. Furlanello, B.D. Gallas, X. Ge, D.B. Megherbi, W.F. Symmans, M.D. Wang, J. Zhang, H. Bitter, B. Brors, P.R. Bushel, M. Bylesjo, M. Chen, J. Cheng, J. Cheng, J. Chou, T.S. Davison, M. Delorenzi, Y. Deng, V. Devanarayan, D.J. Dix, J. Dopazo, K.C. Dorff, F. Elloumi, J. Fan, S. Fan, X. Fan, H. Fang, N. Gonzaludo, K.R. Hess, H. Hong, J. Huan, R.A. Irizarry, R. Judson, D.

Juraeva, S. Lababidi, C.G. Lambert, L. Li, Y. Li, Z. Li, S.M. Lin, G. Liu, E.K. Lobenhofer, J. Luo, W. Luo, M.N. McCall, Y. Nikolsky, G.A. Pennello, R.G. Perkins, R. Philip, V. Popovici, N.D. Price, F. Qian, A. Scherer, T. Shi, W. Shi, J. Sung, D. Thierry-Mieg, J. Thierry-Mieg, V. Thodima, J. Trygg, L. Vishnuvajala, S.J. Wang, J. Wu, Y. Wu, Q. Xie, W.A. Yousef, L. Zhang, X. Zhang, S. Zhong, Y. Zhou, S. Zhu, D. Arasappan, W. Bao, A.B. Lucas, F. Berthold, R.J. Brennan, A. Bunes, J.G. Catalano, C. Chang, R. Chen, Y. Cheng, J. Cui, W. Czika, F. Demichelis, X. Deng, D. Dosymbekov, R. Eils, Y. Feng, J. Fostel, S. Fulmer-Smentek, J.C. Fuscoe, L. Gatto, W. Ge, D.R. Goldstein, L. Guo, D.N. Halbert, J. Han, S.C. Harris, C. Hatzis, D. Herman, J. Huang, R.V. Jensen, R. Jiang, C.D. Johnson, G. Jurman, Y. Kahlert, S.A. Khuder, M. Kohl, J. Li, L. Li, M. Li, Q.Z. Li, S. Li, Z. Li, J. Liu, Y. Liu, Z. Liu, L. Meng, M. Madera, F. Martinez-Murillo, I. Medina, J. Meehan, K. Miclaus, R.A. Moffitt, D. Montaner, P. Mukherjee, G.J. Mulligan, P. Neville, T. Nikolskaya, B. Ning, G.P. Page, J. Parker, R.M. Parry, X. Peng, R.L. Peterson, J.H. Phan, B. Quanz, Y. Ren, S. Riccadonna, A.H. Roter, F.W. Samuelson, M.M. Schumacher, J.D. Shambaugh, Q. Shi, R. Shippy, S. Si, A. Smalter, C. Sotiriou, M. Soukup, F. Staedtler, G. Steiner, T.H. Stokes, Q. Sun, P.Y. Tan, R. Tang, Z. Tezak, B. Thorn, M. Tsyganova, Y. Turpaz, S.C. Vega, R. Visintainer, J. von Frese, C. Wang, E. Wang, J. Wang, W. Wang, F. Westermann, J.C. Willey, M. Woods, S. Wu, N. Xiao, J. Xu, L. Xu, L. Yang, X. Zeng, J. Zhang, L. Zhang, M. Zhang, C. Zhao, R.K. Puri, U. Scherf, W. Tong, R.D. Wolfinger and M. Consortium, The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. *Nat Biotechnol*, 2010. 28(8): p. 827-38.

81. Schmidt, M., R.P. Baum, T. Simon, and R. Howman-Giles, Therapeutic nuclear medicine in pediatric malignancy. *Q J Nucl Med Mol Imaging*, 2010. 54(4): p. 411-28.
82. Paulides, M., W. Stohr, H.J. Laws, N. Graf, M. Lakomek, F. Berthold, K. Schmitt, F. Niggli, H. Jurgens, S. Bielack, E. Koscielniak, T. Klingebiel, and T. Langer, Immunity against tetanus and diphtheria after childhood sarcoma treatment. *Klin Padiatr*, 2010. 222(3): p. 196.
83. Parry, R.M., W. Jones, T.H. Stokes, J.H. Phan, R.A. Moffitt, H. Fang, L. Shi, A. Oberthuer, M. Fischer, W. Tong, and M.D. Wang, k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction. *Pharmacogenomics J*, 2010. 10(4): p. 292-309.
84. Oberthuer, A., D. Juraeva, L. Li, Y. Kahlert, F. Westermann, R. Eils, F. Berthold, L. Shi, R.D. Wolfinger, M. Fischer, and B. Brors, Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients. *Pharmacogenomics J*, 2010. 10(4): p. 258-66.
85. Oberthuer, A., B. Hero, F. Berthold, D. Juraeva, A. Faldum, Y. Kahlert, S. Asgharzadeh, R. Seeger, P. Scaruffi, G.P. Tonini, I. Janoueix-Lerosey, O. Delattre, G. Schleiermacher, J. Vandesompele, J. Vermeulen, F. Speleman, R. Noguera, M. Piqueras, J. Benard, A. Valent, S. Avigad, I. Yaniv, A. Weber, H. Christiansen, R.G. Grundy, K. Schardt, M. Schwab, R. Eils, P. Warnat, L. Kaderali, T. Simon, B. Decarolis, J. Theissen, F. Westermann, B. Brors, and M. Fischer, Prognostic impact of gene expression-based classification for neuroblastoma. *J Clin Oncol*, 2010. 28(21): p. 3506-15.
86. Nevo, I., A. Oberthuer, E. Botzer, O. Sagi-Assif, S. Maman, M. Pasmanik-Chor, N. Kariv, M. Fischer, I. Yron, and I.P. Witz, Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients. *Int J Cancer*, 2010. 126(7): p. 1570-81.

87. Muth, D., S. Ghazaryan, I. Eckerle, E. Beckett, C. Pohler, J. Batzler, C. Beisel, S. Gogolin, M. Fischer, K.O. Henrich, V. Ehemann, P. Gillespie, M. Schwab, and F. Westermann, Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. *Cancer Res*, 2010. 70(9): p. 3791-802.
88. Meinhardt, A., B. Burkhardt, M. Zimmermann, A. Borkhardt, U. Konny, T. Klingebiel, F. Berthold, G. Janka-Schaub, C. Klein, E. Kabickova, W. Klapper, A. Attarbaschi, M. Schrappe, A. Reiter, and g. Berlin-Frankfurt-Munster, Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. *J Clin Oncol*, 2010. 28(19): p. 3115-21.
89. Galldiks, N., L.W. Kracht, F. Berthold, H. Miletic, J.C. Klein, K. Herholz, A.H. Jacobs, and W.D. Heiss, [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. *J Neurooncol*, 2010. 96(2): p. 231-9.
90. Fischer, M. and F. Berthold, The role of complex genomic alterations in neuroblastoma risk estimation. *Genome Med*, 2010. 2(5): p. 31.
91. Fischer, M., T. Bauer, A. Oberthur, B. Hero, J. Theissen, M. Ehrich, R. Spitz, R. Eils, F. Westermann, B. Brors, R. Konig, and F. Berthold, Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. *Oncogene*, 2010. 29(6): p. 865-75.
92. De Preter, K., J. Vermeulen, B. Brors, O. Delattre, A. Eggert, M. Fischer, I. Janoueix-Lerosey, C. Lavarino, J.M. Maris, J. Mora, A. Nakagawara, A. Oberthuer, M. Ohira, G. Schleiermacher, A. Schramm, J.H. Schulte, Q. Wang, F. Westermann, F. Speleman, and J. Vandesompele, Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. *Clin Cancer Res*, 2010. 16(5): p. 1532-41.
93. Creutzig, U., Berthold, F., Bielack, S., Dirksen, U., Koscielniak, E., Körholz, D., Rutkowski, S., Graf, N., Henze, G., Therapie von Tumoren, in *Onkologie - Grundlagen, Diagnostik, Therapie, Entwicklung*, Zeller, Editor. 2010, ecomed: Heidelberg. p. 1-39.
94. Boztug, K., X.Q. Ding, H. Hartmann, L. Ziesenitz, A.A. Schaffer, J. Diestelhorst, D. Pfeifer, G. Appaswamy, S. Kehbel, T. Simon, A. Al Jefri, H. Lanfermann, and C. Klein, HAX1 mutations causing severe congenital neutropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRI. *Am J Med Genet A*, 2010. 152A(12): p. 3157-63.
95. Benz-Bohm, G., B. Hero, A. Gossmann, T. Simon, F. Korber, and F. Berthold, Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary? *Eur J Radiol*, 2010. 74(3): p. e1-5.
96. Hero, B., T. Simon, R. Spitz, K. Ernestus, A.K. Gnekow, H.G. Scheel-Walter, D. Schwabe, F.H. Schilling, G. Benz-Bohm, and F. Berthold, Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. *J Clin Oncol*, 2008. 26(9): p. 1504-10.